Evidence map›Paper›PMID 35413850›Full record

Observational studyJournal of neuroinflammation2022

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.

Christopher Nelke, Frauke Stascheit, Carmen Eckert, Marc Pawlitzki, Christina B Schroeter, Niklas Huntemann, Philipp Mergenthaler, Ercan Arat, Menekse Öztürk, Dirk Foell and 12 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Disease severity as the dominant clinic-available marker of myasthenic crisis occurrence: a single-centre retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 1 country.

Christopher Nelke *Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Frauke Stascheit *Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Department of Neurology With Experimental Neurology, Humboldt-Universität zu Berlin, Berlin, Germany.
Carmen EckertDepartment of Neurology with Institute of Translational Neurology, University and University Hospital Münster, Munster, Germany.
Marc PawlitzkiDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Christina B SchroeterDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Niklas HuntemannDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Philipp MergenthalerCharité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Department of Neurology With Experimental Neurology, Humboldt-Universität zu Berlin, Berlin, Germany.
Ercan AratDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Menekse ÖztürkDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Dirk FoellDepartment for Pediatric Rheumatology and Immunology, University of Münster, Munster, Germany.
Stefanie SchreiberDepartment of Neurology, University of Magdeburg, Magdeburg, Germany.
Stefan VielhaberDepartment of Neurology, University of Magdeburg, Magdeburg, Germany.
Asmae GassaDepartment of Cardiothoracic Surgery, University of Cologne and University Hospital Cologne, Cologne, Germany.
Henning StetefeldDepartment of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Michael SchroeterDepartment of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Benjamin BergerClinic of Neurology and Neurophysiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Andreas TotzeckDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tim HagenackerDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sven G MeuthDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany.
Andreas MeiselCharité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Department of Neurology With Experimental Neurology, Humboldt-Universität zu Berlin, Berlin, Germany.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University and University Hospital Münster, Munster, Germany.
Tobias RuckDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany. tobias.ruck@med.uni-duesseldorf.de.
Heinrich Heine University Düsseldorf · DEUniversity Hospital Münster · DEUniversity of Duisburg-Essen · DECenter for Behavioral Brain Sciences · DEUniversity Hospital Cologne · DECharité - Universitätsmedizin Berlin · DEFreie Universität Berlin · DEUniversity Medical Center Freiburg · DEUniversity of Cologne · DEUniversity of Münster · DE

Funding

Bundesministerium für Bildung und Forschung 01KX2021Einstein Stiftung Berlin 16GW0191
6 · The paper itself

Abstract

backgroundMyasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome.

methodsWe examined a retrospective, observational cohort study of patients diagnosed with MG between 2000 and 2021 with a mean follow-up of 62.6 months after diagnosis from eight tertiary hospitals in Germany. A multivariate Cox regression model with follow-up duration as the time variable was used to determine independent risk factors for MC and disease exacerbation.

results815 patients diagnosed with MG according to national guidelines were included. Disease severity at diagnosis (quantitative MG score or Myasthenia Gravis Foundation of America class), the presence of thymoma and anti-muscle specific tyrosine kinase-antibodies were independent predictors of MC or disease exacerbation. Patients with minimal manifestation status 12 months after diagnosis had a lower risk of MC and disease exacerbation than those without. The timespan between diagnosis and the start of immunosuppressive therapy did not affect risk. Patients with a worse outcome of MC were older, had higher MGFA class before MC and at admission, and had lower vital capacity before and at admission. The number of comorbidities, requirement for intubation, prolonged mechanical ventilation, and MC triggered by infection were associated with worse outcome. No differences between outcomes were observed comparing treatments with IVIG (intravenous immunoglobulin) vs. plasma exchange vs. IVIG together with plasma exchange.

conclusionsMC and disease exacerbations inflict a substantial burden of disease on MG patients. Disease severity at diagnosis and antibody status predicted the occurrence of MC and disease exacerbation. Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients.

Indexed as

Immunoglobulins, IntravenousMyasthenia GravisDisease ProgressionHumansRetrospective StudiesRisk FactorsImmunoglobulins, IntravenousDisease exacerbationMyasthenia gravisMyasthenic crisisPredictorsRisk factors

Identifiers

PMID35413850
PMCPMC9005160
OpenAlexW4223525477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.